Our mission is to become a worldwide reference for education in the field for all professionals involved in the process to disseminate knowledge & skills of Acute Cardiovascular Care.
Our mission is to promote excellence in clinical diagnosis, research, technical development, and education in cardiovascular imaging in Europe.
Our mission is to promote excellence in research, practice, education and policy in cardiovascular health, primary and secondary prevention.
Our mission is to reduce the burden of cardiovascular disease through percutaneous cardiovascular interventions.
Improving the quality of life and reducing sudden cardiac death by limiting the impact of heart rhythm disturbances.
Our mission is to improve quality of life and longevity, through better prevention, diagnosis and treatment of heart failure, including the establishment of networks for its management, education and research.
The ESC Working Groups' goal is to stimulate and disseminate scientific knowledge in different fields of cardiology.
The ESC Councils' goal is to share knowledge among medical professionals practising in specific cardiology domains.
OUR MISSION: TO REDUCE THE BURDEN OF CARDIOVASCULAR DISEASE
Dr. Volker Schaechinger,
Despite recent advances with drug eluting stent (DES) technology instent restenosis (ISR) still represents a clinically relevant failure of percutaneous coronary intervention.
In the first part of the session P. Kala (Brno, CZ) and I. Iakovou (Athens, GR) review the extent of the problem and the pathophysiological background. It was emphasized, that ISR is not a benign disease, since 30 – 60% of patients with ISR present with a prognostically unfavourable acute coronary syndrome. With DES, overall restenosis rate could be reduced from 30% to below 10%, but the actual restenosis risk still varies between patients. Procedural factors predisposing for restenosis are incomplete stent expansion (stent size), geographic mismatch and the use of multiple stents whereas stent technique factors include polymer characteristics, strut coverage and stent fractures. Patient related factors predisposing for ISR are lesion-specific such as bifurcations, ostial lesions or vein graft as well as biological factors such as diabetes or – clinically less assessable – drug resistance or hypersensitivity.
The best way to treat ISR is to prevent it, which is not only possible by using DES. Furthermore, an accurate PCI technique with thoughtful target selection, adequate choice of stent size and implantation pressure is beneficial. It was emphasized that routine use of pressure wire (FFR measurement), especially in patients with multivessel disease, would identify lesions, which would not have to be treated (and therefore cannot develop ISR).
In the second part, B. Scheller (Homburg, Germany) and B. Chevalier (Massy, France) reviewed current treatment options for ISR. Meanwhile, additional DES implantation is the established way to treat ISR, for both failure of a BMS or a DES. Compared to only balloon angioplasty, recurrent (second) ISR can be reduced by 65% with an additional DES. However, to have multiple layers of stent struts in the coronary artery may be a limit to this approach. Therefore, drug eluting balloons (DEB) may be a favourable alternative to treat ISR, which has been also considered in the recent 2010 ESC revascularization guidelines. First small studies indicate that DEB may reduce second ISR to below 10% with DEB, compared to 20% with DES or 50% with balloon angioplasty only. However, these results have to be confirmed in ongoing larger trials, powered for clinical endpoints. In addition, class effect of DEB may not be assumed and therefore, only DEB adequately evaluated in clinical trials may be used.
Challenges of in-stent restenosis
© 2017 European Society of Cardiology. All rights reserved